Ring Carbon Of Each Of The Two Nitrogen Containing Hetero Rings Is Bonded Directly To Chalcogen (e.g., Both Rings May Be Bonded To The Same Oxygen Atom Or To Different Oxygen Atoms, Etc.) Patents (Class 548/519)
  • Patent number: 11548890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 10, 2023
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Patent number: 11498898
    Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: November 15, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomomi Ikemoto, Hideya Mizufune, Toshiaki Nagata, Takeshi Yamasaki
  • Patent number: 10550348
    Abstract: The present invention relates to a lubricating composition containing (a) an oil of lubricating viscosity; and (b) a compound selected from the group consisting of: (i) an ester-containing heterocycle; (ii) an amide-containing heterocycle; and (iii) a pyrimidine, wherein the ester-containing heterocycle and the amide-containing heterocycle have a hydrocarbyl group containing 6 to 40 carbon atoms. The invention further provides for a method of supplying an internal combustion engine with the lubricating composition.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: February 4, 2020
    Assignee: The Lubrizol Corporation
    Inventors: Patrick E. Mosier, Jason R. Brown, Matthew D. Gieselman, Calvin W. Schroeck, Seth L. Crawley, William R. S. Barton, William C. Ward, Jr.
  • Patent number: 9351484
    Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 31, 2016
    Assignee: ISP INVESTMENTS INC.
    Inventors: Osama M. Musa, Kolazi S. Narayanan
  • Patent number: 9266831
    Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: February 23, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tomomi Ikemoto, Toshiaki Nagata, Naohiro Fukuda
  • Patent number: 9260416
    Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 16, 2016
    Assignee: AMIRA PHARMACEUTICALS, INC.
    Inventors: Jeffrey Roger Roppe, Timothy Andrew Parr, John Howard Hutchinson
  • Patent number: 9181255
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: November 10, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher
  • Patent number: 9068137
    Abstract: The invention relates to compositions containing a basic oil or base oil, 10 to 50 percent by weight of ether pyrrolidone carboxylic acids of formula (1) or the salts thereof of formula (1), wherein R1 represents C8-C30-alkyl, C8-C30-alkenyl, C6-C30-alyl, C7-C30-alkylaryl, M represents hydrogen, alkali metal, alkaline earth metal, or ammonium, X represents C2-C6-alkylene, or a poly(oxyalkylene) group of formula (2), wherein I is a number ranging from 1 to 50, m, n are numbers ranging from 0 to 50 independently of l and independently of one another, R2, R3, and R4 independently represent hydrogen, CH3, or CH2CH3, Y represents C2-C6-alkylene, said compositions further containing a specific amount of a pH regulator/neutralizer such that a 5 percent by weight emulsion of the composition in deionized water has a pH ranging from 7 to 11.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: June 30, 2015
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Rainer Kupfer, Carsten Cohrs, Alexander Roesch
  • Patent number: 9012490
    Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 21, 2015
    Assignee: Howard University
    Inventors: Evaristus A. Nwulia, Amol Kulkarni
  • Patent number: 8946446
    Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: February 3, 2015
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
  • Patent number: 8758880
    Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (Ib) or (Ic) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: June 24, 2014
    Assignee: BASF SE
    Inventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jürg Kirner, Mathieu G. R. Turbiez
  • Patent number: 8685992
    Abstract: The present invention refers to compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I): wherein: R1 and R2 represent, independently, an optionally substituted C6-C10 aryl radical or an optionally substituted heteroaryl radical; A and M represent, independently, a methylene group or a single bond, in which case the adjacent aromatic ring would be attached directly to the amide group; the Y?Z group represents together and indistinctly an oxygen atom, a sulfur atom, a cis-vinylidene group, an imino group, or a methine group with a sp2-hybridized carbon atom; X represents indistinctly a methine group, a cis-vinylidene group or a nitrogen atom; and W represents a hydroxyl group, an optionally substituted C1-C6 alkyl group, an optionally substituted heteroaryl group or an optionally substituted C6-C10 aryl group; or a salt, solvate or prodrug thereof, as well as to the process for their preparation and the use thereof for the treatment of cancer.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: April 1, 2014
    Assignees: Universidad del País Vasco, Ikerschem, S.L.
    Inventors: Fernando Pedro Cossío Mora, Aizpea Zubia Olascoaga, Yosu Vara Salazar, Eider Ion San Sebastián Larzabal, Dorleta Otaegui Ansa, María del Carmen Masdeu Margalef, Eneko Aldaba Arévalo
  • Publication number: 20140079723
    Abstract: Methods and materials for treating various diseases and medical conditions with meso-biliverdin compositions. In addition methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin are provided.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 20, 2014
    Applicant: UTAH STATE UNIVERSITY
    Inventors: Jon Y. Takemoto, Dong Chen, Cheng-Wei T. Chang, Jonathan Wood
  • Publication number: 20140051742
    Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.
    Type: Application
    Filed: March 11, 2013
    Publication date: February 20, 2014
    Inventors: Evaristus A. Nwulia, Amol Kulkarni
  • Publication number: 20140045698
    Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: ISP INVESTMENTS INC.
    Inventors: Osama M. Musa, Kolazi S. Narayanan
  • Publication number: 20130324687
    Abstract: The invention provides compounds and monomers having a carbonate linkage. The monomers can be used to form homopolymers or can be coupled with other monomers to provide a wide variety of non-homopolymers. The invention further provides a wide variety of compositions comprising the compounds, monomers, and polymers. In the exemplary structures below, Q, A, R, and n are as described herein.
    Type: Application
    Filed: January 17, 2012
    Publication date: December 5, 2013
    Applicant: ISP Investments Inc.
    Inventors: Ezat Khosravi, Osama M. Musa
  • Patent number: 8575349
    Abstract: The present invention relates to novel derivatives of 1-alkyl-6-oxo-piperidine-3-carboxylic acids and 1-alkyl-5-oxo-pyrrolidine-3-carboxylic acids represented by Formula I: wherein n is an integer of 1 or 2; R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen and methyl; X is selected from the group consisting of oxygen and nitrogen; and R5 is hydrogen or a C1-C7 linear or branched acyclic hydrocarbon group, or R5 together with X form a 3- to 8-membered heterocyclic hydrocarbon group, and their uses as cooling compounds.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: November 5, 2013
    Assignee: International Flavors & Fragrances Inc.
    Inventor: Arkadiusz Kazimierski
  • Publication number: 20130289223
    Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.
    Type: Application
    Filed: December 17, 2012
    Publication date: October 31, 2013
    Inventors: J. Paul SANTERRE, Mei LI
  • Publication number: 20130289284
    Abstract: Provided are modified natural compounds that are produced, at least in part, from (A) at least one epoxidized and/or maleated natural fatty acid, or epoxidized and/or maleated natural oil, and (B) at least one lactam having at least one hydroxyl functional group, wherein the lactam may be in a blend with one or more optional alcohol(s). Among other properties, the modified natural compounds may exhibit dispersibility or solubility characteristics in water and/or alcohols. The invention further provides a wide variety of compositions comprising the modified natural compounds.
    Type: Application
    Filed: July 25, 2011
    Publication date: October 31, 2013
    Inventors: Osama M. Musa, Ezat Khosravi
  • Patent number: 8518874
    Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: August 27, 2013
    Assignee: Virobay, Inc.
    Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
  • Patent number: 8431721
    Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 30, 2013
    Assignee: Constar International, Inc.
    Inventors: Girish Nilkanth Deshpande, Paul David Weipert, Michael W. Ensley
  • Publication number: 20130096318
    Abstract: Methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: Utah State University
    Inventor: Utah State University
  • Publication number: 20130079528
    Abstract: A method of making a compound of Formula I? comprises reacting a compound of the formula DLCHO, with a compound of the formula to produce the compound of Formula I?. Methods of using the compounds are also described, particularly as intermediates for the synthesis of porphyrin rods, which porphyrin rods are in turn useful for (among other things) the production of molecular memory devices.
    Type: Application
    Filed: August 31, 2012
    Publication date: March 28, 2013
    Inventors: Jonathan S. Lindsey, Lianhe Yu, Patchanita Thamyongkit, Anil D. Bhise
  • Publication number: 20130035484
    Abstract: A compound of formula (I): which is substantially free of any of the corresponding compound of formula (IB): methods of making such compounds, and the further transformation of such compounds.
    Type: Application
    Filed: April 15, 2011
    Publication date: February 7, 2013
    Applicant: SPIROGEN DEVELOPMENTS SÀRL
    Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien
  • Patent number: 8362035
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Patent number: 8232293
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Publication number: 20120148514
    Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.
    Type: Application
    Filed: November 15, 2011
    Publication date: June 14, 2012
    Applicant: ISP INVESTMENTS INC.
    Inventors: Osama M. Musa, Kolazi S. Narayanan
  • Patent number: 8163793
    Abstract: The invention relates to a compound of formula (I) wherein A, R1-R6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: April 24, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Rubén Alvarez Sánchez, David Banner, Simona M. Ceccarelli, Uwe Grether, Wolfgang Haap, Peter Hartman, Guido Hartmann, Hans Hilpert, Holger Kuehne, Harald Mauser, Jean-Marc Plancher
  • Publication number: 20120088705
    Abstract: The subject of the invention is an etherpyrrolidone carboxylic acid of the formula (1) in which R1 is a C1-C6 hydrocarbon group with 1-4 oxy groups R2 is H, CH3, CH2CH3 (A-O) is a (poly)alkylene glycol unit containing one or more C2-C4 alkoxy groups or a mixture of plural C2-C4 alkoxy groups, at least one alkoxy group being a butoxy or propoxy group M is hydrogen, alkali metal, alkaline earth metal or an ammonium group y is 1 or 2 x is 1, 2, 3 or 4.
    Type: Application
    Filed: May 19, 2010
    Publication date: April 12, 2012
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Rainer Kupfer, Carsten Cohrs, Alexander Roesch
  • Publication number: 20110312890
    Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
    Type: Application
    Filed: August 1, 2011
    Publication date: December 22, 2011
    Applicant: SIGNATURE R&D HOLDINGS, LLC
    Inventor: V. Ravi Chandran
  • Patent number: 8067651
    Abstract: The invention provides compounds of the formula 1 in which A is a C2- to C4-alkylene group x is from 1 to 100 R1 is C1-C30-alkyl, C2-C30-alkenyl, C7-C30-alkylaryl R2 is an aliphatic, cycloaliphatic or aromatic radical which contains at least one structural unit of the formula 2 ?and y is from 0 to 100, with the proviso that y is from 1 to 100 when R2 is of the formula 2, and their use in amounts of from 0.01 to 2% by weight for preventing the formation of gas hydrates in aqueous phases which are in contact with a gaseous, liquid or solid organic phase.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: November 29, 2011
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Dirk Leinweber, Alexander Roesch, Michael Feustel
  • Patent number: 7985594
    Abstract: The present invention provides methods for performing dynamic nuclear polarization using biradicals with a structure of formula (I) as described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a biradical of formula (I) and an analyte with at least one spin half nucleus; (b) polarizing the at least one spin half nucleus of the analyte by irradiating the frozen sample with radiation having a frequency that excites electron spin transitions in the biradical; (c) optionally melting the sample to produce a molten sample; and (d) detecting nuclear spin transitions in the at least one spin half nucleus of the analyte in the frozen or molten sample. The present invention also provides biradicals with a structure of formula (I) with the proviso that Q1 and Q2 are different when X1 and X2 are —O—. The present invention also provides methods for making biradicals with a structure of formula (IA) as described herein.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: July 26, 2011
    Assignee: Massachusetts Institute of Technology
    Inventors: Robert G. Griffin, Kan-Nian Hu, Timothy M. Swager, Changsik Song, Eric Dane
  • Publication number: 20110171171
    Abstract: A compound of Formula 1.1A: 1.1A or salt thereof, as well as methods of making compounds of Formula 1.1A, methods of using compounds of Formula 1.1A to treat proliferative disorders such as cancer, and related compounds, composition, and methods.
    Type: Application
    Filed: June 26, 2009
    Publication date: July 14, 2011
    Applicant: Aegera Therapeutics, Inc.
    Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, James B. Jaquith, Stephen Morris
  • Patent number: 7923562
    Abstract: Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: April 12, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James K. Chen, Surajit Sinha, Ilya Shestopalov, Xiaohu Ouyang
  • Patent number: 7897776
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: March 1, 2011
    Assignee: Salutria Pharmaceuticals LLC
    Inventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
  • Publication number: 20100297405
    Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (1b) or (1c) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Application
    Filed: October 16, 2008
    Publication date: November 25, 2010
    Applicant: BASF SE
    Inventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jurg Kirner, Mathieu G.R. Turbiez
  • Patent number: 7772159
    Abstract: The invention provides a new process for the preparation of polypyrrolinones (I) of various sizes which have found to be useful peptidomimetics. One aspect of the invention is a new process utilizing ?-amino-?-substituted-valerolactones as synthons. A second aspect of the invention is a process for the synthesis of polypyrrolinones using solid-phase techniques.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: August 10, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Amos B. Smith, III, Hu Liu, Hiroyuki Ikumura, Ralph F. Hirschmann
  • Patent number: 7745641
    Abstract: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(?O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like}; R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: June 29, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Chikara Murakata, Nobuyoshi Amishiro, Toshiyuki Atsumi, Yoshinori Yamashita, Takeshi Takahashi, Ryuichiro Nakai, Hisashi Tagaya, Hiroko Takahashi, Jun Funahashi, Junichiro Yamamoto, Yuichi Fukuda
  • Publication number: 20090270454
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
    Type: Application
    Filed: April 23, 2008
    Publication date: October 29, 2009
    Inventors: M. David Weingarten, Charles Q. Meng, James A. Sikorski, Raymond Ng, Wei Zhang
  • Patent number: 7608592
    Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: October 27, 2009
    Assignee: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
  • Publication number: 20090203762
    Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.
    Type: Application
    Filed: February 2, 2009
    Publication date: August 13, 2009
    Inventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
  • Patent number: 7498447
    Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: March 3, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Danny T. Dinh
  • Publication number: 20090043146
    Abstract: The invention provides compounds of the formula 1 in which A is a C2- to C4-alkylene group x is from 1 to 100 R1 is C1-C30-alkyl, C2-C30-alkenyl, C7-C30-alkylaryl R2 is an aliphatic, cycloaliphatic or aromatic radical which contains at least one structural unit of the formula 2 ?and y is from 0 to 100, with the proviso that y is from 1 to 100 when R2 is of the formula 2, and their use in amounts of from 0.01 to 2% by weight for preventing the formation of gas hydrates in aqueous phases which are in contact with a gaseous, liquid or solid organic phase.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 12, 2009
    Inventors: Dirk Leinweber, Alexander Roesch, Michael Feustel
  • Patent number: 7482475
    Abstract: Disclosed herein is a compound having a structure Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: January 27, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Robert M. Burk
  • Patent number: 7476747
    Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Danny T. Dinh
  • Patent number: 7309800
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: December 18, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
  • Patent number: 7196112
    Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: March 27, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Wen-Cherng Lee, R. Blake Pepinsky, Mark Cornebise, Daniel Scott, Russell C. Petter
  • Patent number: 7193067
    Abstract: Mono- and Bis-Azo/Hydrazone Pyrrole Pigments and Methods for preparing same.
    Type: Grant
    Filed: August 23, 2005
    Date of Patent: March 20, 2007
    Inventors: Terence Chamberlain, Norman W. Smith, Donald T. DeRussy
  • Patent number: 7151118
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: December 19, 2006
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
  • Patent number: RE40525
    Abstract: A racemate diastereoisomer and optical isomer of a compound of formula (I): wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)—; a carboxyl derivative of formula R4—O—C(O)—; an amide derivative of formula R4—N(R5)—C(O)—; a thioamide derivative of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5 is H or C1-6 alkyl; and Y is H or C1-6 alkyl; R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl; R2 is C2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 30, 2008
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Montse Llinas-Brunet, Murray D. Bailey, Dale R. Cameron, Anne-Marie Faucher, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Marc-André Poupart, Jean Rancourt, Youla S. Tsantrizos, Dominik M. Wernic